文献速递造血干细胞移植与细胞治疗

造血干细胞移植受者COVID-19的临床特征与结局:观察性队列研究

Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study.
PubMed 文献 · Lancet Haematol · 2021-01-19

该研究基于CIBMTR登记数据,纳入318例确诊COVID-19的HSCT受者,旨在描述其特征与结局。主要结局为COVID-19诊断后30天总生存,异基因和自体HSCT受者分别为68%和67%。年龄≥50岁、男性、移植后12个月内发生COVID-19与异基因HSCT受者死亡风险升高相关。

要点

  • HSCT受者COVID-19后30天总生存异基因68%、自体67%。
  • 异基因HSCT死亡风险因素:年龄≥50岁、男性、移植后12月内。
  • 自体HSCT中淋巴瘤指示疾病死亡风险高于浆细胞病/骨髓瘤。

核心结论

  • 发生COVID-19的自体和异基因HSCT受者总体生存较差,需加强监测和积极治疗。

研究设计与样本

  • 观察性队列研究,基于CIBMTR 2020年3月27日起收集的COVID-19数据,纳入318例HSCT受者,数据截止2020年8月12日。
  • 主要结局为COVID-19诊断后30天总生存,采用Kaplan-Meier法和Cox比例风险模型分析。

主要发现

  • 318例中,轻症155例(49%),需机械通气的重症45例(14%),其中异基因28例(15%)、自体17例(13%)。
  • 异基因HSCT受者从移植到COVID-19诊断中位17个月(IQR 8-46),自体为23个月(IQR 8-51)。
  • 异基因HSCT受者中34例(18%)在COVID-19诊断前6个月内接受免疫抑制治疗。
  • 异基因HSCT受者30天总生存68%(95%CI 58-77),自体HSCT受者67%(95%CI 55-78)。

临床怎么用

  • 对HSCT受者发生COVID-19应加强监测,尤其高龄、男性、近期移植及淋巴瘤患者。
  • 需采取积极治疗措施以改善HSCT受者COVID-19结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Haematopoietic stem-cell transplantation (HSCT) recipients are considered at high risk of poor outcomes after COVID-19 on the basis of their immunosuppressed status, but data from large studies in HSCT recipients are lacking. This study describes the characteristics and outcomes of HSCT recipients after developing COVID-19. METHODS: In response to the pandemic, the Center for International Blood and Marrow Transplant Research (CIBMTR) implemented a special form for COVID-19-related data capture on March 27, 2020. All patients-irrespective of age, diagnosis, donor type, graft source, or conditioning regimens-were included in the analysis with data cutoff of Aug 12, 2020. The main outcome was overall survival 30 days after a COVID-19 diagnosis. Overall survival probabilities were calculated using Kaplan-Meier estimator. Factors associated with mortality after COVID-19 diagnosis were examined using Cox proportional hazard models. FINDINGS: 318 HSCT recipients diagnosed with COVID-19 were reported to the CIBMTR. The median time from HSCT to COVID-19 diagnosis was 17 months (IQR 8-46) for allogeneic HSCT recipients and 23 months (8-51) for autologous HSCT recipients. The median follow-up of survivors was 21 days (IQR 8-41) for allogeneic HSCT recipients and 25 days (12-35) for autologous HSCT recipients. 34 (18%) of 184 allogeneic HSCT recipients were receiving immunosuppression within 6 months of COVID-19 diagnosis. Disease severity was mild in 155 (49%) of 318 patients, while severe disease requiring mechanical ventilation occurred in 45 (14%) of 318 patients-ie, 28 (15%) of 184 allogeneic HSCT recipients and 17 (13%) of 134 autologous HSCT recipients. At 30 days after the diagnosis of COVID-19, overall survival was 68% (95% CI 58-77) for recipients of allogeneic HSCT and 67% (55-78) for recipients of autologous HSCT. Age 50 years or older (hazard ratio 2·53, 95% CI 1·16-5·52; p=0·020); male sex (3·53; 1·44-8·67; p=0·006), and development of COVID-19 within 12 months of transplantation (2·67, 1·33-5·36; p=0·005) were associated with a higher risk of mortality among allogeneic HSCT recipients, and a disease indication of lymphoma was associated with a higher risk of mortality compared with plasma cell disorder or myeloma (2·41, [1·08-5·38]; p=0·033) in autologous HSCT recipients. INTERPRETATION: Recipients of autologous and allogeneic HSCT who develop COVID-19 have poor overall survival. These data emphasise the need for stringent surveillance and aggressive treatment measures in HSCT recipients who develop COVID-19. FUNDING: American Society of Hematology; Leukemia and Lymphoma Society; National Cancer Institute; National Heart, Lung and Blood Institute; National Institute of Allergy and Infectious Diseases; National Institutes of Health; National Cancer Institute; Health Resources and Services Administration; Office of Naval Research.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Sharma A, Bhatt NS, St Martin A, et al. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. Lancet Haematol. 2021. PMID: 33482113. doi:10.1016/S2352-3026(20)30429-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。